Sequoia Capital China completed almost $15 million Series B investment in Beijing-based Deep Intelligent Pharma DIP, a Chinese startup that provides artificial intelligence AI technology for drug development, on September 28, though it was not announced until October 9.
DIP develops AI technologies throughout the whole drug RD process and most recently released an AI system that monitors adverse reactions to drugs a fresh application for AI use in the medical field. It means that the drug development process can be fully monitored from its early status to after-sales.
This is a new area for Chinese AI companies that has much scope for...
¬ Haymarket Media Limited. All rights reserved.
